Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on its Marketing Authorisation Application (MAA) for Janssen-Cilag International's (Janssen-Cilag ) antibiotic Zeftera, for the treatment of complicated skin and soft tissue infections.
Subscribe to our email newsletter
Cilag International has given Basilea Pharmaceutica a notice of termination of the worldwide license, development and co-promotion agreement between the parties. The compound, including pending applications and in-market products, will be transitioned back to Basilea under the terms of the license agreement.
Zeftera (ceftobiprole medocaril for injection, henceforth known as ceftobiprole) is a cephalosporin antibiotic indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms in patients 18 years of age and older.
Janssen-Cilag International and Cilag GmbH International are Johnson & Johnson companies.